An intermediate access protocol for selumetinib for treatment of neurofibromatosis type 1 with inoperable, progressive/symptomatic plexiform neurofibromas Purpose To provide access to selumetinib to people with neurofibromatosis type 1 (NF1) with plexiform neurofibromas that cannot be operated on. Criteria Patients ≥ 2 years old with disease before the age of 18 years old Diagnosis of neurofibromatosis type 1 (NF1) Plexiform neurofibromas that cannot be surgically completely removed Details There is no maximum duration for this study as long as it is deemed that a response is being obtained. Interested in more information? Contact Us: Hematology Oncology Associates IRB: Quorum IRB Number: Trial Type: NA Sponsor: Astra Zenca